Exelixis Inc., of Alameda, Calif., reported it generated total revenues of $228.6 million in the fourth quarter and $853.8 million for the full year. The revenues included the sale of Cabometyx (cabozantinib) for the treatment of advanced renal cell carcinoma (RCC) whose net product revenues were $176.2 million for the fourth quarter and $619.3 million for the full year.